Figure 1.

Nomogram of treatment indicators for chronic hepatitis B without liver cirrhosis for (A) HBeAg-positive patients and (B) HBeAg-negative patients. Gradation toward dark gray suggests immediate treatment, and gradation toward white suggests observation and monitoring. Intermediate gradation suggests the need for fibrosis assessment before determining treatment according to the international guidelines and the Korean Association for the Study of Liver Guidelines. The initiation of antiviral therapy is indicated by a noninvasive fibrosis test suggesting evidence of significant fibrosis or a liver biopsy showing significant necroinflammation or fibrosis (≥A2 or ≥F2). HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; ULN, upper limit of normal; NA, nucleos(t)ide analog.